Education
About Us
Working with TipRanks
Follow Us
Bright Minds Biosciences (DRUG)
NASDAQ:DRUG
DRUG Stock Chart & Stats
$84.00
$0.82(2.04%)
At close: 4:00 PM EST
$84.00
$0.82(2.04%)
Day’s Range― - ―
52-Week Range$23.18 - $93.40
Previous Close$40.4
Volume34.65K
Average Volume (3M)102.09K
Market Cap
$654.62M
Enterprise Value$204.27M
Total Cash (Recent Filing)$51.39M
Total Debt (Recent Filing)$141.03K
Price to Earnings (P/E)―
Beta4.80
Next Earnings
Feb 18, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding7,785,761
10 Day Avg. Volume115,326
30 Day Avg. Volume102,086
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.14
Price to Sales (P/S)0.00
P/FCF Ratio-3.42
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.33K
Enterprise Value/Ebitda-22.73
Forecast
1Y Price Target
$89.74Price Target Upside6.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementThe introduction of BMB-105 as a next-generation 5-HT2C agonist and dedicated PWS candidate complements ongoing clinical work with BMB-101, further extending Bright Minds' leadership in 5-HT2C agonism.
Pipeline DevelopmentWith strong mechanistic rationale, early safety validation, and a growing clinical pipeline, Bright Minds continues to execute on its goal of delivering first-in-class, functionally selective serotonergic therapies for underserved neurological and psychiatric conditions.
Strategic ExpansionBright Minds broadens its 5-HT2C clinical footprint with expansion into Prader-Willi syndrome (PWS), marking a significant strategic step in extending its serotonergic platform beyond seizure disorders into metabolic and neurobehavioral disease.
Bears Say
Bright Minds Biosciences News
DRUG FAQ
What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was $23.18 and its highest was $93.40 in the past 12 months.
What is Bright Minds Biosciences’s market cap?
Bright Minds Biosciences’s market cap is $654.62M.
When is Bright Minds Biosciences’s upcoming earnings report date?
Bright Minds Biosciences’s upcoming earnings report date is Feb 18, 2026 which is in 59 days.
How were Bright Minds Biosciences’s earnings last quarter?
Bright Minds Biosciences released its earnings results on Dec 18, 2025. The company reported -$0.562 earnings per share for the quarter, beating the consensus estimate of -$0.568 by $0.007.
Is Bright Minds Biosciences overvalued?
According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued.
Does Bright Minds Biosciences pay dividends?
Bright Minds Biosciences does not currently pay dividends.
What is Bright Minds Biosciences’s EPS estimate?
Bright Minds Biosciences’s EPS estimate is -0.88.
How many shares outstanding does Bright Minds Biosciences have?
Bright Minds Biosciences has 7,785,761 shares outstanding.
What happened to Bright Minds Biosciences’s price movement after its last earnings report?
Bright Minds Biosciences reported an EPS of -$0.562 in its last earnings report, beating expectations of -$0.568. Following the earnings report the stock price went down -10.445%.
Which hedge fund is a major shareholder of Bright Minds Biosciences?
Currently, no hedge funds are holding shares in DRUG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bright Minds Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.74 (6.83% Upside)
$89.74 (6.83% Upside)
Blogger Sentiment
Bullish
DRUG Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
―
20 days / 200 days
Momentum
145.60%
12-Months-Change
Fundamentals
Return on Equity
-30.79%
Trailing 12-Months
Asset Growth
736.23%
Trailing 12-Months
Company Description
Bright Minds Biosciences
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
DRUG Stock 12 Month Forecast
Average Price Target
$89.74
▲(6.83% Upside)
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
NervGen Pharma
―
Eupraxia Pharmaceuticals
―
Ownership Overview
14.17% Insiders
1.36% Mutual Funds
46.21% Other Institutional Investors
35.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---